Clinical trials: Systemic Lupus
Lupus Nephritis
Aurinia Early Urinary Protein Reduction Predicts Response
An exploratory study assessing the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks in subjects taking voclosporin 23.7 mg twice daily (BID) in combination with standard of care in…
- Trial name
- AURION (NCT02949973)
- Testing
- voclosporin
- Where
- 2 sites in Malaysia
- Volunteers
- 10 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Lupus Nephritis
Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)
Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).
- Trial name
- NCT05540665
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 10 more
- Volunteers
- 19 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus, SLE
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.
- Trial name
- ALE06 (NCT01946880)
- Testing
- Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 102 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Erythematosus, Systemic
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus…
- Trial name
- NCT03161483
- Testing
- CC-220
- Where
- 184 sites in United States, Argentina and 13 more
- Volunteers
- 289 people
- Sponsor
- Celgene
Systemic Lupus Erythematosus (SLE)
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib given alone or as the ABBV-599 combination…
- Trial name
- NCT04451772
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Lupus Nephritis
Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).
- Trial name
- TULIP-LN1 (NCT02547922)
- Testing
- Anifrolumab
- Where
- 80 sites in United States, Argentina and 15 more
- Volunteers
- 147 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus
The primary objective of this study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (SC) CEP-33457 for injection every 4 weeks over 72 weeks (18 doses) in participants with systemic…
- Trial name
- NCT01240694
- Testing
- CEP-33457
- Where
- 85 sites in United States, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Cephalon, Inc.
Systemic Lupus Erythematosus
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
This study will assess the effect of a 24-week withdrawal followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with stable low systemic lupus erythematosus (SLE) disease…
- Trial name
- NCT02119156
- Testing
- Belimumab
- Where
- 20 sites in United States, China and 2 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Lupus Nephritis
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
The purpose of this study is to learn whether atacicept treatment leads to improvement in kidney function in subjects with active lupus nephritis in combination with mycophenolate mofetil (MMF) and corticosteroids.
- Trial name
- NCT00573157
- Testing
- Atacicept, Mycophenolate mofetil, Corticosteroids
- Where
- 20 sites in United States, Czechia and 3 more
- Volunteers
- 6 people
- Sponsor
- EMD Serono
Systemic Lupus Erythematosus
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT03252587
- Testing
- BMS-986165
- Where
- 192 sites in United States, Argentina and 15 more
- Volunteers
- 363 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
Low-dose IL-2( Interleukin-2) Treatment in SLE
This clinical study will test the efficacy and safety of low dose IL-2 treatment in Systemic lupus erythematosus.
- Trial name
- NCT02084238
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Systemic Lupus Erythematosus
Reducing Disparities in Medication Adherence in SLE
This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
- Trial name
- NCT03738826
- Testing
- Behavioral Intervention
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus
Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus
The study will compare the efficacy of the usual education materials to individualized computerized decision guide on decision conflict of patients with lupus nephritis making treatment decisions regarding immunosuppressive…
- Trial name
- NCT02319525
- Testing
- Computerized patient decision-aid, Usual care (lupus pamphlet)
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- University of Alabama at Birmingham
Lupus Nephritis
Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus…
- Trial name
- NCT00705367
- Testing
- Abatacept
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms.
- Trial name
- NCT05879718
- Testing
- PF-06823859
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Pfizer
Systemic Lupus Erythematosus
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
- Trial name
- SLE-BRAVE I (NCT03616912)
- Testing
- Baricitinib
- Where
- 184 sites in United States, Australia and 16 more
- Volunteers
- 830 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus
Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis
This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates…
- Trial name
- NCT04971590
- Testing
- Participant completed survey, Medical chart review
- Where
- 6 sites in Kuwait, Oman and 2 more
- Volunteers
- 193 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus (SLE)
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and…
- Trial name
- SLEek (NCT03978520)
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 160 sites in United States, Argentina and 19 more
- Volunteers
- 341 people
- Sponsor
- AbbVie
Lupus Erythematosus, Systemic
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
- Trial name
- NCT03517722
- Testing
- Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
- Where
- 204 sites in United States, Argentina and 18 more
- Volunteers
- 516 people
- Sponsor
- Janssen Research & Development, LLC